



*Review*

## Role of mushrooms in gestational diabetes mellitus

Vandana Gulati<sup>1\*</sup>, Mansi Dass Singh<sup>1</sup>, Pankaj Gulati<sup>2</sup>

<sup>1</sup> Department of Nutritional Medicine, Endeavour College of Natural Health, Melbourne 3000, Victoria, Australia

<sup>2</sup> Department of Biosciences, Endeavour College of Natural Health, Melbourne 3000, Victoria, Australia

\* **Correspondence:** Email: [Vandana.gulati@endeavour.edu.au](mailto:Vandana.gulati@endeavour.edu.au); Tel: +61396559507.

**Abstract:** Many studies have shown that plant-based diets and Mediterranean diets can lower the risk of development of gestational diabetes mellitus. Plants have been the main source of medicines since ancient times. Despite tremendous advances in medicinal chemistry, synthetic drugs have not provided cures to many diseases due to their adverse side effects or diminution in response after prolonged use. Medicinal mushrooms have been used traditionally as an anti-diabetic food for centuries especially in countries such as China, Japan, India and Korea. These are source of natural bioactive compounds. The bioactive constituents are polysaccharides, proteins, dietary fibres, lectins, lactones, alkaloids, terpenoids, sterols and phenolic compounds which have various health benefits. This review will focus on recent examples of diverse types of mushrooms that have been validated by scientific evaluation as having promising activity for the prevention and/or treatment of gestational diabetes mellitus. Dietary components and plant-derived molecules can be used in the future to complement current treatment strategies for gestational diabetes mellitus.

**Keywords:** Gestational diabetes mellitus; medicinal mushrooms; polysaccharides; dietary fibres; phenolic compounds; anti-diabetic food

---

### 1. Introduction


Gestational diabetes is a form of hyperglycemia. It is a common metabolic disorder during pregnancy. According to ‘World Health Organization’ (WHO), gestational diabetes is defined as hyperglycaemia that is first recognised during pregnancy and is observed to precedes to type 2 diabetes in up to one third of women later in life [1]. Series of endocrine, metabolic and vascular

changes take place during pregnancy to fulfil the demand of energy and nutrient needs of the foetus. GDM develops when pancreatic  $\beta$ -cell is not sufficient to compensate for the decreased insulin sensitivity and due to which there is increase in post-prandial free fatty acids, hepatic glucose production, insulin resistance and glucose production [2]. Although, glucose homeostasis is restored after delivery but there is high risk of development of type 2 diabetes mellitus in future. Gestational diabetes indicates the underlying frequency of type 2 diabetes for any ethnic and population group with incidences rising globally needing huge health care and economic costs [3].


GDM is clearly a major public health issue internationally, especially among those of non-European descent and data from previous studies also revealed that GDM was more prevalent in women with family history of diabetes, women who were obese and parous [4].

## 2. Pathophysiology

During pregnancy, there is an increase in oestrogen and progesterin concentration which further leads to decrease fasting glucose, delay in gastric emptying and increase in appetite. Tissue sensitivity to insulin decreases as gestation progresses and therefore, post-prandial glucose concentration increases. To counteract this, pancreatic  $\beta$ -cell of the mother have to increase insulin secretion to regulate glucose concentrations and GDM females are unable to produce sufficient insulin (Figure 1). Insulin resistance is also caused by defects in receptors of insulin -signalling cascade. The down-regulation of insulin receptor substrate-1 (IRS-1) decreases insulin-mediated glucose uptake in skeletal muscles. Genetic variations have also been associated with greater risk of developing gestational diabetes (Figure 2) [5].



**Figure 1.** Onset of GDM in pregnant females.



**Figure 2.** Factors which increase the onset of GDM in females.


### 3. Management of gestational diabetes mellitus

Blood glucose monitoring is very important to manage GDM. Diet and nutrition must be carefully monitored, and exercise can effectively regulate the blood glucose concentrations and can reduce the risks of complications for a mother as well as her baby due to hyperglycaemia [5]. Maintaining healthy body weight, abstinence from cigarette smoking, restricting refined sugars and Trans fats, consumption of low glycaemic foods, soluble fibres and calorie restriction are the preventive measures in blood glucose regulation [6].

Plants have been used historically for medicinal purposes worldwide. Plants are the rich sources of fibres, vitamins, minerals and phytonutrients and have shown beneficial effects in management of diabetes, cardiovascular disorders, obesity and some cancers [7]. In recent years, mushrooms and seaweeds have gained an interest of many researchers and now they have moved on to explore mushrooms to control and manage post-prandial hyperglycemia [8]. Mushrooms have been used in Traditional Chinese Medicine (TCM) and as functional foods in nutraceuticals for their anti-diabetic and anti-obesity effects [9]. The worldwide mushroom industry has grown, and rate of consumption has been increased at a rapid rate since the late 1990s [10].

Mushrooms have been part of culinary culture across the globe and have been valued for their unique flavor. More than 2000 mushroom species exist in nature but only 25 species have been accepted as food [11]. Eighty five percent of the world's mushroom supply is from five main genera such as *Agaricus* (*A. bisporus* and *A. brasilensis*) contributing 30% world's cultivated mushrooms. *Pleurotus*, second one with 5 to 6 cultivated species, constitutes about 27% of world's output and then *Lentinula edodes* (Shiitake) contributes 17%, whereas *Auricularia* and *Flammulina* constitute for only 6% and 5% respectively [10].

Mushrooms belong to phylum Basidiomycota and order, Agaricales. They have a fruiting body composed of a stipe (stalk), pileus (cap) and lamellae (gills) and mycelium, the root absorbs the nutrients [12]. *Gymnopilus edulis* seaweed is potential glucosidase enzyme inhibitor, *Lenitus edodes*, *Ganoderma lucidum* have shown to possess anti-diabetic effects in various studies [13]. Several beneficial nutritional effects of mushrooms have been identified (Figure 3) [14].



**Figure 3.** Nutritional effects of mushrooms.

The aim of this article is to review the relevant literature on use of different mushrooms in managing diabetes and gestational diabetes mellitus.

#### 4. Medicinal mushrooms with potential anti-diabetic activities

##### 4.1. *Ganoderma lucidum* (Lingzhi/Reishi)

*Ganoderma lucidum* belongs to the family Ganodermaceae which is widely used for longevity and health promotion. It is commonly known as ‘Ligzhi’ in China and ‘Reishi’ in Japan. The bioactive compounds are polysaccharides,  $\beta$ -glucans, lectins, organic germanium, phenols, steroids, amino acids, lignins, mycins and vitamins. *Ganoderma* is considered as golden medicinal fungus [15]. *Ganoderma lucidum* is often combined with another mushroom, *Cordyceps sinensis* which is thought to increase potency of *Ganoderma lucidum* [16].

##### 4.2. *Lentinus edodes* (Shiitake mushrooms)

Shiitake mushrooms have been used to treat common cold for hundreds of years. These mushrooms contain high fibre, high levels of  $\beta$ -glucans, proteins, lipids, carbohydrates, minerals,

vitamin B1, B2 and C, ergosterol, lectins and lentinans. Studies have shown that shiitake mushrooms could alleviate the damage of pancreatic  $\beta$ -cells, promote insulin synthesis and lower plasma glucose levels. An ex-polymer of *L. edodes* reduced plasma glucose and increased insulin synthesis in streptozotocin-induced diabetic rats compared to normal rats [8].

#### 4.3. *Ophiocordyceps sinensis*

*Ophiocordyceps* earlier known as *Cordyceps sinensis* has been used historically as a medicinal mushroom. It has only been found growing at high altitudes in Qinghai-Tibetan plateau and due to high demand and declining harvest, this has become the one of the most expensive mushrooms used in oriental medicine. This mushroom is only found in co-habitation with larvae of an insect, needs rarefied atmosphere, mineral rich soil and low temperature which makes artificial cultivation challenging. *Cordyceps* has a unique profile of secondary metabolites and thus, considered as world's most costly medicinal mushroom [17]. Various animal and human studies have shown antihyperglycemic, anti-atherosclerotic, anti-hypertensive, antioxidant and cholesterol lowering effects of *Cordyceps sinensis* [16].

#### 4.4. *Agaricus blazei* Murill

ABM is native to Brazil and widely grown in Japan. This mushroom is traditionally believed to fight physical and emotional stress, stimulate immune system, manage diabetes, cholesterol, digestive issues. Ergosterols, lignins and polysaccharides are the main bioactive constituents [18]. The polysaccharides,  $\alpha$ -glucans,  $\beta$ -glucans have been shown to possess immune-modulatory and anti-mutagenic activity in both *in-vitro* as well as *in-vivo* studies [8]. The natural polysaccharides of this mushroom have shown to be effective in regulating diabetes by the mechanisms given below [19].

- (a) Elevation of plasma insulin and decrease of pancreatic glucagon
- (b) Increase in insulin sensitivity and improvement of insulin resistance
- (c) Inhibition of  $\alpha$ -glucosidase enzyme
- (d) Increase of hepatic glycogen and inhibition of sugar dysplasia
- (e) Increased use of glucose from peripheral tissues
- (f) Scavenging free radicals and lipid peroxidation

#### 4.5. *Grifola frondosa*

*Grifola frondosa*, also known as Maitake mushrooms has varied medicinal properties and is popular in Korea, China and Japan. Chinese people have been consuming Maitake mushrooms for hundreds of years for its enticing taste. These mushrooms possess anti-tumour, immune-regulatory, anti-diabetic, beneficial effects against hepatitis and HIV/AIDS [20].

#### 4.6. *Pleurotus pulmonarius* (Grey Oyster Mushroom)

This type of mushroom is an excellent anti-diabetic food. It contains polysaccharides, vitamins and minerals, dietary fibres and rich in essential amino acids. Oyster mushroom is consumed all over the world due to its high nutritive value and flavour. It can be cultivated within wide-range of

temperatures and possess wide range of health benefits [21].

#### 4.7. *Antrodia cinnanomea*

This mushroom is native to Taiwan with various medicinal properties. This has mainly used to treat diarrhoea, abdominal pain, hypertension, cancer and toxicities caused by various foods and drugs [11].

#### 4.8. *Panellus serotinus* (Mukitake)

This mushroom is the most delicious edible mushroom in Japan. This mushroom has found be very beneficial for liver and helps to prevent the development of non-alcoholic fatty liver disease [11].

#### 4.9. *Auricularia auricular*

*Auricularia* species are widely cultivated in China, Taiwan, Thailand, Philippines, Indonesia, Malaysia [10]. Most species of *Auricularia* are edible and possess medicinal properties. *A. polytricha* (Wood ear mushrooms) and *A. auricula-judae* (black fungus) are anti-tumour, anti-coagulant and cholesterol lowering, *A. auricula-judae* has also shown hypoglycemic properties [11].

#### 4.10. *Flammulina velutipes*

This mushroom is traditionally used for soups in China. Bioactive constituents are dietary fibre and polysaccharides. *Flammulina* is hypoglycemic, cholesterol lowering and anti-oxidant [11].

### 5. Hypoglycemic effects of mushrooms

There have been numerous investigations conducted on rats to understand effect of different variety of medicinal mushrooms on underlying biomarkers of diabetes; some of these studies are summarized in Table 1. All these studies have either used polysaccharides, protein complexes, or compounds extracted from fruiting bodies, cultured mycelium, or cultured broth of medicinal mushrooms. This section includes most of the medicinal mushrooms that have been investigated for their potential in Diabetes along with the demonstrated mechanism of action. The medicinal mushroom extracts are invaluable source of a variety of:

- (1) enzymes such as laccase, superoxide dismutase, glucose oxidase, peroxidase;
- (2) polysaccharides such as  $\beta$ -D-glucans, glucuronoxylomannan;
- (3) lectins, glucoproteins, proteins, polysaccharide-protein complexes,
- (4) lipopolysaccharides,
- (5) terpenoids, alkaloids, sterols, phenolic substances, metal chelating agents [19].

These components have been demonstrated to target various deranged carbohydrate metabolic pathways thereby lowering blood glucose and insulin concentrations in type 2 diabetics as shown in Table 2 and 1. Efforts are currently underway to quantify these compounds for their therapeutic usage in diabetes and other conditions.

**Table 1.** Summary of some experiments on rats to demonstrate hypoglycaemic effects of medicinal mushrooms (MM).

Type of medicinal mushroom	Form of mushroom	Dose	Result	Possible mechanisms
<i>Agaricus brasiliensis</i> and <i>Ganoderma lucidum</i> [22]	Mycelia powder	1 g/kg for 14 days	MM extracts reduced complications in microcirculation induced by hyperglycaemia via promotion of ion homeostasis and structural and functional states of erythrocyte membranes.	Influenced physiological balance of process of sialylation and desialylation, regulated ion charge on the surface membrane of red blood cells, normalized aggregation properties, and elevated the structural recovery of oligosaccharide chains of erythrocyte membrane surface glycoconjugates.
<i>Lentinus edodes</i> ( <i>Agaricomycetes</i> ) [23]	Lyophilized and reconstituted	Doses of 100 or 200 mg/kg/d of lyophilized and reconstituted <i>L. edodes</i> for 19 days of gestation	Reduced glucose in plasma, urea, triglycerides, and aspartate aminotransferase.	Improved liver function and stabilized insulin response.
<i>Maitake -Grifola frondosa</i> (Higher Basidiomycetes) [24]	Fermented mycelia, broth, or mycelia plus broth	1 g/kg-per day for two weeks	Hyperglycaemia and cell mediated inflammation was reduced.	Decreased inflammation by downregulating IFN- $\gamma$ IL-4, and IL-6 IL-4 as well as significantly improved the productions of tumor-necrosis factor- $\alpha$ .
<i>Cracked-Cap-Phellinus rimosus</i> (Higher Basidiomycetes) [25]	Extract	<i>P. rimosus</i> (50 and 250 mg/kg) and glibenclamide (0.65 mg/kg) for 30 days	Significant reduction in blood glucose, triacylglycerol, total cholesterol, LDL-cholesterol, and liver function enzymes, and increased serum insulin, liver glycogen, and HDL-cholesterol levels.	Possible insulinogenic and antioxidant mechanisms as improved antioxidant status was observed in pancreas, liver, and kidney tissues with associated fall in thiobarbituric acid- reactive substances.
<i>Agaricus brasiliensis</i> and <i>Ganoderma lucidum</i> [26]	Powdered mushrooms	Dose of 1 g/kg body weight	Reduced Oxidative-nitrative stress.	Decreased the activity of the NO synthase, as well as positive corrective action on the L-arginine/NO system and the ratio between p53 and Bcl-2 proteins in white blood cells, as well as on apoptotic index reduction.

*Continued on next page*

Type of medicinal mushroom	Form of mushroom	Dose	Result	Possible mechanisms
<i>Pleurotus ostreatus</i> and <i>P. cystidiosus</i> [27]	Freeze-dried and powdered	Different doses (250, 500, 750, 1000, and 1250 mg/kg/body weight) to normal rats and a single dose of 500mg/kg body wt. to diabetic rats	A single dose significantly ( $P < 0.05$ ) reduced the serum glucose levels in diabetic rats.	Hypoglycaemic action.
<i>Pleurotus florida</i> [28]	Polysaccharide extract	200- and 400-mg/kg doses	Hypocholesterolaemic, anti-inflammatory and hypoglycaemic actions.	Lowered glucose concentrations, serum cholesterol, triglycerides, and urine glucose and ketones. Also caused significant fall in MDA and NO, but enhanced superoxide dismutase, catalase and active glutathione.
<i>Grifola frondosa</i> [29]	$\alpha$ -glucan	300 or 100 mg/kg	Reduced injury to $\beta$ cells of pancreas, hypoglycaemic and hypocholesterolaemic.	Lowered triglycerides, cholesterol, free fatty acid, improved inflammatory action.
<i>Pleurotus ostreatus</i> [30]	Total polysaccharides extract	100, 200, and 400 mg/kg/d for 4 weeks	Reduced hyperglycemia and hyperlipidemia levels, improved insulin resistance, and increased glycogen storage, reduced the risk of oxidative damage.	Enhanced GSK3 phosphorylation and GLUT4 translocation. Also increased endogenous antioxidants' (superoxide dismutase, catalase, and glutathione peroxidase) activities and decreased MDA.
<i>Coprinus comatus</i> [31]	Polysaccharide fractions (ethanol based)	1000 mg/kg in 12 min and 21 days of injection at the same dosage	Short and long term hypoglycaemic action.	Hypoglycemic activity is possibly mediated via immune stimulation.



**Table 2.** Medicinal mushrooms active constituents and pharmacological action.

Name of the mushroom	Active ingredient	Pharmacological action
<i>Agaricus bisporus</i> [32]	Thiamine, ascorbic acid, vitamin D <sub>2</sub> as well as minerals like folates, ergothioneine (ET) and polyphenols	Reduced plasma glucose, significant decrease in triglycerides concentrations, plasma total cholesterol, low density cholesterol
<i>Agrocybe cylindracea</i> [33]	Glucan and heteroglycan	Hypoglycemic activity
<i>Agaricus campestris</i> [34]	Aqueous fruiting body extracts	Insulin releasing and insulin-like activity
<i>Agaricus subrufescens/Agaricus blazei</i> [35–37]	High levels of valuable minerals like potassium, phosphorus, calcium, magnesium and zinc Beta-glucans	Anti-hyperglycemic. Suppressed the increase in HbA1c and oxidative stress
<i>Auricularia auricula</i> [38,39]	Water soluble polysaccharide from fruit body	Lowering plasma glucose and significantly lowered blood urea nitrogen (BUN) and uric acid (UA) in serum, and protein concentration in urine by altering the anti-oxidative system and nuclear factor kappa B-related
<i>Coprinus comatus</i> [40,41]	It is rich in trace elements like vanadium, chromium, zinc, magnesium, copper, iron, and nickel and Comatin an inhibitor of the non-enzymatic glycosylation (NEG) reaction	Helped in lowering the level of blood glucose and improved the glucose tolerance
<i>Cordyceps sinensis</i> [42,43]	It is rich in trace elements like cadmium, lead, arsenic, copper, nickel, silver, chromium, and mercury	Increase serum insulin concentration and decreased serum fructosamine concentration
<i>Ganoderma lucidum</i> [44]	Polysaccharides (Ganoderan A and B, glucans), proteoglycans (FYGL), and triterpenoids	FYGL was able to enhance insulin sensitive and to decrease hepatic glucose output along with the increased level of adipocyte and skeletal muscle glucose disposal

Name of the mushroom	Active ingredient	Pharmacological action
<i>Grifola frondosa</i> [45]	Alpha-glucan (MT-alpha-glucan)	Alpha- glucan was able to increase the insulin sensitivity and ameliorate insulin resistance.
<i>Hericium erinaceus</i> [46,47]	Polysaccharides, oligosaccharide, sterol, fatty acid, erinacine and hericenone,	It was able to reduce the blood glucose levels, liver glycogen content and also able to enhance insulin production.
<i>Inonotus obliquus</i> [48,49]	Polysaccharides and polyphenols	Polysaccharide has shown to inhibit <i>dipeptidyl peptidase 4</i> (DPP4) enzymes and induce translocation of GLUT4 receptor
<i>Lentinus edodes</i> [50]	Provitamin D2 (ergosterol), glycogen-like polysaccharides, (1-4)-, (1-6)-D-glucans and exopolysaccharide	Exopolysaccharide has been reported to decrease the plasma glucose level and increased plasma insulin
<i>Pleurotus pulmonaris</i> [51,52]	Profilin-1, glyceraldehyde-3-phosphate dehydrogenase and guanide	Guanide is known to cause exocytosis of insulin containing granules and reduces fasting plasma glucose concentration
<i>Tremella aurantia</i> [53,54]	Acidic polysaccharide	Exhibited hypoglycemic and ameliorated the symptoms of diabetes
<i>Tremella fuciformis</i> [55]	Glucuronoxylomannan and exopolysaccharides	Hypoglycemic activity was attributed to the presence of gluronoxylomannan whereas; insulin sensitivity was enhanced due to the exopolysaccharides reported in the mushroom
<i>Wolfiporia cocos</i> [56,57]	Dehydrotumulosic acid, polyporenic acid C, pachymic acid, dehydrotrametenolic acid, and dehydroeburicoic acid.	Acts as an insulin sensitizer in glucose tolerance tests and reduces hyperglycemia
<i>Wolfiporia extensa</i> [57,58]	Triterpenoids like pachymic acid and polysaccharides.	Reduced postprandial blood glucose levels and enhanced insulin sensitivity

One of such studies experimented with the mycelia powder extracted from *Agaricus brasiliensis* and *Ganoderma lucidum*. The extract was fed to streptozotocin (STZ)-induced diabetic Wistar outbred white male rats. The study demonstrated hypoglycaemic effects when compared to control group as evidenced by lowered blood glucose and glycosylated hemoglobin concentrations [22]. This study also demonstrated that when the mushroom preparations were orally administered at a dose of 1 g/kg for 14 days to diabetic rats, the physiological balance between sialylation and desialylation processes was restored and integrity of erythrocyte membrane surface glycoconjugates strengthened. Thus, mushrooms extract prevented dysregulation of iron homeostasis erythrocyte membranes thereby strengthening them and causing hypoglycemic and anti-anemic action [22]. Another animal experiment tested the polysaccharides and  $\alpha$ -glucans extracted from the body of *Grifola Frondosa* and reported decreased concentrations of fasting plasma glucose, triglycerides, cholesterol and increased serum insulin in diabetic mouse [20]. Another study utilized Maitake mushrooms (*Grifola frondosa*) and reported lowered blood glucose concentration. The fall in blood glucose may be attributed to Vanadium and an alpha-glucose inhibitor present in this variety of mushrooms. [8]. Vanadium complexes have been demonstrated to have insulin-mimetic as well as insulin potentiation properties [59] as observed in *in vivo*, animal and human studies. It facilitates regulation of glucose metabolism in diabetics as it plays a pivotal role being a cofactor for enzymes that participate in insulin signalling leading to GLUT4 translocation [60–62].

Further, a study reported reduction in hyperglycaemia induced oxidative-nitrative stress on rats with gestational diabetes [gestational diabetes was induced by streptozotocin (80 mg/kg), administered intraperitoneally] when medicinal mushroom powder was orally administered at a dose of 1 g/kg body weight [26]. Another experiment of daily dose of 100 or 200 mg/kg of lyophilized and reconstituted *Lentinus edodes* to diabetic rats on 1st to the 19th day of gestation, observed reduced plasma catalase, glucose, urea, triglycerides, and aspartate aminotransferase [23].

Ingestion of mycelia, broth, and mycelia plus broth of *Maitake (Grifola frondosa)* has also been demonstrated to alleviate the increase in 2 h postprandial blood glucose. The experiments showed significant improvement in innate immunity by modulating levels of inflammatory cytokines such as tumor-necrosis factor- $\alpha$ , macrophages productions of IFN- $\gamma$  from the T-leukocytes, IL-4, and IL-6 from the monocytes and IL-4 from the T-splenocytes type 2 diabetes mellitus rats [24].

*Pleurotus ostreatus* and *P. cystidiosus* ingestion has also been shown to reduce blood glucose level, improved serum lipid profile, liver glycogen, liver function enzymes, and enzymic antioxidants activities in pancreas, liver, and kidney in STZ-induced diabetic rats [27]. Another mushroom *Phellinus rimosus* has been shown to increase antioxidant status in pancreas, liver, and kidney tissues with concomitant decrease in levels of thiobarbituric acid- reactive substances thus showcasing significant hypoglycemic and hypolipidemic activities that may be related to its insulinogenic and antioxidant effect of medicinal mushrooms [25].

Studies by Huang et al. [63,64] demonstrated that polysaccharides from *Pleurotus tuber-regium* mushrooms have antihyperglycemic properties and they reduce oxidative stress in diabetic rats that were fed a high fat diet.

Another interesting compound-Ternatin (a highly methylated cyclic heptapeptide) isolated from mushroom *Coriolus versicolor* was reported to inhibit fat accumulation in 3T3-L1 adipocytes and suppressed the development of hyperglycemia via decreasing the SREBP-1c mRNA level in hepatocytes [65]. Another experimental study was conducted on pregnant rats (diabetes was induced by streptozotocin) in which the effects of reconstituted lyophilized powder and dehydrated

mushrooms powder of *Agaricus blazei*, *Ganoderma lucidum* or *Lentinula edodes* at daily dose of 100mg/kg were investigated from gestation day 1 to 19. Mushrooms *G. lucidum* and *L. edodes* reduced glucose levels in glycemic curve in response to glucose tolerance test thereby suggesting potential of mushrooms as functional foods in management of diabetes [66].

In a clinical study, oral hypoglycaemic effect of freeze-dried suspensions and powder prepared from *Pleurotus ostreatus* and *Pleurotus cystidiosus* on both healthy and type 2 diabetic humans was investigated. A dose of 50mg/kg/body weight was administered to both groups while on a diet control, followed by a glucose load. A significant reduction ( $P < 0.05$ ) in fasting and postprandial serum glucose levels of healthy volunteers and decreased postprandial serum glucose levels and increased the serum insulin levels ( $P < 0.05$ ) of type 2 diabetic patients was observed. The researchers simultaneously conducted animal study to understand the mechanism of action using same dose. The medicinal mushrooms demonstrated possible increased glucokinase activity and insulin secretion that improved the utilization of glucose by peripheral tissues, inhibited glycogen synthase kinase and promoted glycogen synthesis [67].

A clinical study on 71 participants with type 2 diabetes evaluated the safety and efficacy of Ganopoly (polysaccharides extracted from *G. lucidum*) for 12 weeks at 1800mg thrice a day. Significant decrease in the mean glycosylated haemoglobin (HbA1c) was observed with decrease in post-prandial glucose. The study found Ganopoly to be efficacious and safe in lowering blood glucose concentrations [68]. A double blind, randomised, placebo-controlled trial evaluated the safety and efficacy of *Ganoderma lucidum* for the treatment of hyperglycemia and cardiovascular risk factors of metabolic syndrome. *Ganoderma lucidum* extract was used with or without *Cordyceps sinensis* in dose of 3 grams/day for 16 weeks. Eighty four, 18 years and older participants with type 2 diabetes mellitus and metabolic syndrome were randomised to one of three intervention groups – *Ganoderma lucidum*, *Ganoderma lucidum* with *Cordyceps sinensis* or placebo. The HbA1C and fasting plasma glucose were measured and the results were not found to be clinically significant or statistically significant on hyperglycemia, hypertension, or lipid profile in adults with metabolic syndrome or type 2 diabetes [16]. The effects on metabolic profile could be attributed to the presence of polysaccharides that are mainly classified as  $\beta$ -glucan polymers [owing to  $\beta$ -(1 $\rightarrow$ 3) linkages with some  $\beta$ -(1 $\rightarrow$ 6) branches along with presence of chitin, mannans, galactans, and xylans]. Pancreas enzymes are not equipped to hydrolyze the  $\beta$ -glucosidic bond, thereby allowing for prebiotics action of glucans that modulates gut microbiota, improves utilization, dietary energy, gene expression and gut permeability. Further polysaccharide glucan content of medicinal mushrooms [69,70]:

- (1) Reduces serum glucose and lipoproteins;
- (2) Enhances serum insulin;
- (3) Improves liver PPAR- $\alpha$  expression and mRNA expression of protein levels;
- (4) Provides structural support to pancreatic  $\beta$ -cells;
- (5) Antioxidant and anti-inflammatory action.

Thus, medicinal mushrooms may have multiple metabolic actions that may cause improvement in insulin response and glucose homeostasis at cellular levels. It may also reduce underlying inflammation and strengthen epithelial and hepatic cells to prevent damage from any type of diabetes including GDM. However, there is insufficient evidence to draw definitive conclusions about the efficacy of individual medicinal mushrooms for Gestational diabetes unless human randomized trials are completed.

## 6. Discussion

There is association between gestational diabetes and type 2 diabetes and it has been observed that women who have had gestational diabetes have at least seven-fold risk of developing type 2 diabetes in future compared to those women who have had a normal pregnancy. The risk factors are family history of diabetes, raised body-mass index, increased age, Asian ethnicity [3]. There are currently few clinical studies that have investigated the effects of mushrooms on diabetes or gestational diabetes mellitus in humans. The sample size of these studies was small, all dietary factors were not evaluated for confounding effects, various insulin and glucose control functions were not assessed consistently in all the studies which makes it difficult to formulate guidelines. Furthermore, there is not enough evidence on the dose, dosage form and side-effects of medicinal mushrooms that may be effective for pregnant females. According to American Herbal Products Association Botanical Safety Handbook, both mushrooms *Ganoderma lucidum* and *Cordyceps sinensis* are listed as safest drug class (Class 1 Drug) with no known herb-drug interactions. However, there is lack of scientific data on a safety and efficacy of *Ganoderma* dosage but 1.5 gms to 9 gms of dried extract per day is recommended by Chinese medicine experts [16]. There is immense scope to investigate the duration of supplementation to manage glucose irregularities in females with gestational diabetes. Studies are also required to investigate whether maternal supplementation of medicinal mushrooms influences growth and physiology of infants. There is also lack of consistency of clinical data for long term consumption to demonstrate the efficacy and safety in GDM females and also the quality control and standardisation data for the production of mushroom supplements is needed for its nutraceutical use [70].

## 7. Conclusion

The current review highlights the potential of medicinal mushroom in management of Gestational diabetes: a disease with serious, long-term consequences for both baby as well as mother. The heterogeneity of the data from animal and human study prevented a statistical analysis/meta-analysis, hence a qualitative review was conducted. GDM is a growing health concern and evidence now suggests that screening, early detection and management can greatly improve outcomes for both baby and a mother. There is no uniformity in the screening and diagnostic methods around the world which leads to underdiagnoses and under management of gestational diabetes.

The present review has shown that polysaccharides,  $\beta$ -glucan, vanadium and other nutrients in mushrooms may address deranged metabolic profile in diabetics thereby improving immune responses, liver and pancreatic enzyme functions and exert prebiotic effect and improve gut permeability. Dietary source is always a popular and economical choice to manage a metabolic disorder in a community. Therefore, future research on mushroom species among humans is required that could assist in testing dosage and form of consumption for better health outcomes among gestational diabetic women.

## Conflict of interest

All authors declare no conflicts of interest in this paper.

## References

1. Buchanan TA, Xiang AH (2005) Gestational diabetes mellitus. *J Clin Invest* 115: 485–491.
2. Konstanze M, Holger S, Mathias F (2012) Leptin, adiponectin and other adipokines in gestational diabetes mellitus and pre-eclampsia. *Clin Endocrinol* 76: 2–11.
3. Bellamy L, Casas JP, Hingorani AD, et al. (2009) Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. *Lancet* 373: 1773–1779.
4. Bener A, Saleh NM, Al-Hamaq A (2011) Prevalence of gestational diabetes and associated maternal and neonatal complications in a fast-developing community: global comparisons. *Int J Women's Health* 3: 367–373.
5. Reece EA, Leguizamón G, Wiznitzer A (2009) Gestational diabetes: the need for a common ground. *Lancet* 373: 1789–1797.
6. Hod M, Kapur A, Sacks DA, et al. (2015) The International Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: A pragmatic guide for diagnosis, management, and care. *Int J Gynecol Obstet* 131: S173–S211.
7. Craig WJ (2010) Nutrition Concerns and Health Effects of Vegetarian Diets. *Nutr Clin Pract* 25: 613–620.
8. De Silva DD, Rapior S, Hyde KD, et al. (2012) Medicinal mushrooms in prevention and control of diabetes mellitus. *Fungal Divers* 56: 1–29.
9. Martel J, Ojcius DM, Chang CJ, et al. (2017) Anti-obesogenic and antidiabetic effects of plants and mushrooms. *Nat Rev Endocrinol* 13: 149–160.
10. Royse DJ, Singh M (2014) A global perspective on the high five: Agaricus, Pleurotus, Lentinula, Auricularia & Flammulina, 1–6.
11. Valverde ME, Hernandez-Prez T, Paredes-Lopez O (2015) Edible Mushrooms: Improving Human Health and Promoting Quality Life. *Int J Microbiol* 2015: 376387.
12. Horowitz S (2011) Medicinal Mushrooms: Research Support for Modern Applications of Traditional Uses. *Altern Complem Ther* 17: 323–329.
13. Mohamed M, Nassef D, Waly E, et al. (2012) Earliness, Biological efficiency and basidiocarp yield of *Pleurotus ostreatus* and *P. columbinus* oyster mushrooms in response to different sole and mixed substrates. *Assiut J Agric Sci* 43: 91–114.
14. Gargano ML, van Griensven LJ, Isikhuemhen OS, et al. (2017) Medicinal mushrooms: Valuable biological resources of high exploitation potential. *Plant Biosys* 151: 548–565.
15. Deepalakshmi K, Mirunalini S (2011) Therapeutic properties and current medical usage of medicinal mushroom: *Ganoderma lucidum*. *Inter J Pharm Sci Res* 2: 1922–1929.
16. Klupp NL, Kiat H, Bensoussan A, et al. (2016) A double-blind, randomised, placebo-controlled trial of *Ganoderma lucidum* for the treatment of cardiovascular risk factors of metabolic syndrome. *Sci Rep* 6: 29540.
17. Holliday JC, Cleaver MP (2008) Medicinal Value of the Caterpillar Fungi Species of the Genus *Cordyceps* (Fr.) Link (Ascomycetes). A Review. *Int J Med Mushrooms* 10: 219–234.
18. Firenzuoli F, Gori L, Lombardo G (2008) The Medicinal Mushroom *Agaricus blazei* Murrill: Review of Literature and Pharmacotoxicological Problems. *Evid Based Complement Alternat Med* 5: 3–15.
19. Vitak T, Yurkiv B, Wasser S, et al. (2017) Effect of medicinal mushrooms on blood cells under conditions of diabetes mellitus. *World J Diabetes* 8: 187–201.

20. Lei H, Guo S, Han J, et al. (2012) Hypoglycemic and hypolipidemic activities of MT- $\alpha$ -glucan and its effect on immune function of diabetic mice. *Carbohydr Polym* 89: 245–250.
21. Khan MA, Tania M (2012) Nutritional and medicinal importance of Pleurotus mushrooms: An overview. *Food Rev Int* 28: 313–329.
22. Vitak TY, Wasser SP, Nevo E, et al. (2015) Structural Changes of Erythrocyte Surface Glycoconjugates after Treatment with Medicinal Mushrooms. *Int J Med Mushrooms* 17: 867–878.
23. Maschio BH, Gentil BC, Caetano ELA, et al. (2017) Characterization of the Effects of the Shiitake Culinary-Medicinal Mushroom, *Lentinus edodes* (Agaricomycetes), on Severe Gestational Diabetes Mellitus in Rats. *Int J Med Mushrooms* 19: 991–1000.
24. Chen YH, Lee CH, Hsu TH, et al. (2015) Submerged-Culture Mycelia and Broth of the Maitake Medicinal Mushroom *Grifola frondosa* (Higher Basidiomycetes) Alleviate Type 2 Diabetes-Induced Alterations in Immunocytic Function. *Int J Med Mushrooms* 17: 541–556.
25. Rony KA, Ajith TA, Janardhanan KK (2015) Hypoglycemic and Hypolipidemic Effects of the Cracked-Cap Medicinal Mushroom *Phellinus rimosus* (Higher Basidiomycetes) in Streptozotocin-Induced Diabetic Rats. *Int J Med Mushrooms* 17: 521–531.
26. Yurkiv B, Wasser SP, Nevo E, et al. (2015) The Effect of *Agaricus brasiliensis* and *Ganoderma lucidum* Medicinal Mushroom Administration on the L-arginine/Nitric Oxide System and Rat Leukocyte Apoptosis in Experimental Type 1 Diabetes Mellitus. *Int J Med Mushrooms* 17: 339–350.
27. Jayasuriya WJ, Suresh TS, Abeytunga D, et al. (2012) Oral hypoglycemic activity of culinary-medicinal mushrooms *Pleurotus ostreatus* and *P. cystidiosus* (higher basidiomycetes) in normal and alloxan-induced diabetic Wistar rats. *Int J Med Mushrooms* 14: 347–355.
28. Ganeshpurkar A, Kohli S, Rai G (2014) Antidiabetic potential of polysaccharides from the white oyster culinary-medicinal mushroom *Pleurotus florida* (higher Basidiomycetes). *Int J Med Mushrooms* 16: 207–217.
29. Lei H, Guo S, Han J, et al. (2012) Hypoglycemic and hypolipidemic activities of MT- $\alpha$ -glucan and its effect on immune function of diabetic mice. *Carbohydr Polym* 89: 245–250.
30. Zhang Y, Hu T, Zhou H, et al. (2016) Antidiabetic effect of polysaccharides from *Pleurotus ostreatus* in streptozotocin-induced diabetic rats. *Int J Biol Macromol* 83: 126–132.
31. Zhou S, Liu Y, Yang Y, et al. (2015) Hypoglycemic Activity of Polysaccharide from Fruiting Bodies of the Shaggy Ink Cap Medicinal Mushroom, *Coprinus comatus* (Higher Basidiomycetes), on Mice Induced by Alloxan and Its Potential Mechanism. *Int J Med Mushrooms* 17: 957–964.
32. Jeong SC, Jeong YT, Yang BK, et al. (2010) White button mushroom (*Agaricus bisporus*) lowers blood glucose and cholesterol levels in diabetic and hypercholesterolemic rats. *Nutr Res* 30: 49–56.
33. Kiho T, Sobue S, Ukai S (1994) Structural features and hypoglycemic activities of two polysaccharides from a hot-water extract of *Agrocybe cylindracea*. *Carbohydr Res* 251: 81–87.
34. Gray AM, Flatt PR (1998) Insulin-releasing and insulin-like activity of *Agaricus campestris* (mushroom). *J Endocrinol* 157: 259–266.
35. Wisitrassameewong K, Karunarathna SC, Thongklang N, et al. (2012) *Agaricus subrufescens*: A review. *Saudi J Biol Sci* 19: 131–146.

36. Kerrigan RW (2005) *Agaricus subrufescens*, a cultivated edible and medicinal mushroom, and its synonyms. *Mycologia* 97: 12–24.
37. Niwa A, Tajiri T, Higashino H (2011) *Ipomoea batatas* and *Agaricus blazei* ameliorate diabetic disorders with therapeutic antioxidant potential in streptozotocin-induced diabetic rats. *J Clin Biochem Nutr* 48: 194–202.
38. Vincent HK, Innes KE, Vincent KR (2007) Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity. *Diabetes Obes Metab* 9: 813–839.
39. Hu XY, Liu CG, Wang X, et al. (2017) Hypoglycemic and anti-diabetic nephritis activities of polysaccharides separated from *Auricularia auricular* in diet-streptozotocin-induced diabetic rats. *Exp Ther Med* 13: 352–358.
40. Ding ZY, Lu YJ, Lu ZX, et al. (2010) Hypoglycaemic effect of comatin, an antidiabetic substance separated from *Coprinus comatus* broth, on alloxan-induced-diabetic rats. *Food Chem* 121: 39–43.
41. Lv YT, Han LN, Yuan C, et al. (2009) Comparison of Hypoglycemic Activity of Trace Elements Absorbed in Fermented Mushroom of *Coprinus comatus*. *Biol Trace Elem Res* 131: 177–185.
42. Guo JY, Han CC, Liu YM (2010) A Contemporary Treatment Approach to Both Diabetes and Depression by *Cordyceps sinensis*, Rich in Vanadium. *Evid Based Complement Alternat Med*: 7: 387–389.
43. Nie S, Cui SW, Xie MY, et al. (2013) Bioactive polysaccharides from *Cordyceps sinensis*: Isolation, structure features and bioactivities. *Bioact Carbohydrates Dietary Fibre* 1: 38–52.
44. Pan D, Zhang D, Wu JS, et al. (2013) Antidiabetic, Antihyperlipidemic and Antioxidant Activities of a Novel Proteoglycan from *Ganoderma lucidum* Fruiting Bodies on db/db Mice and the Possible Mechanism. *PLoS One* 8: e68332.
45. Hong L, Xun M, Wutong W (2007) Anti-diabetic effect of an alpha-glucan from fruit body of maitake (*Grifola frondosa*) on KK-Ay mice. *J Pharm Pharmacol* 59: 575–582.
46. Chaiyasut C, Sivamaruthi BS (2017) Anti-hyperglycemic property of *Herichium erinaceus* – A mini review. *Asian Pac J Trop Biomed* 7: 1036–1040.
47. Liang B, Guo ZD, Xie F, et al. (2013) Antihyperglycemic and antihyperlipidemic activities of aqueous extract of *Herichium erinaceus* in experimental diabetic rats. *BMC Complement Altern Med* 13: 253.
48. Geng Y, Lu ZM, Huang W, et al. (2013) Bioassay-Guided Isolation of DPP-4 Inhibitory Fractions from Extracts of Submerged Cultured of *Inonotus obliquus*. *Molecules* 18: 1150–1161.
49. Wang J, Wang C, Li S, et al. (2017) Anti-diabetic effects of *Inonotus obliquus* polysaccharides in streptozotocin-induced type 2 diabetic mice and potential mechanism via PI3K-Akt signal pathway. *Biomed Pharmacother* 95: 1669–1677.
50. Bisen P, Baghel RK, Sanodiya BS, et al. (2010) *Lentinus edodes*: A macrofungus with pharmacological activities. *Curr Med Chem* 17: 2419–2430.
51. Wahab NAA, Abdullah N, Aminudin N (2014) Characterisation of Potential Antidiabetic-Related Proteins from *Pleurotus pulmonarius* (Fr.) Quél. (Grey Oyster Mushroom) by MALDI-TOF/TOF Mass Spectrometry. *Biomed Res Int* 2014: 131607.
52. Badole SL, Patel NM, Thakurdesai PA, et al. (2008) Interaction of Aqueous Extract of *Pleurotus pulmonarius* (Fr.) Quél-Champ. with Glyburide in Alloxan Induced Diabetic Mice. *Evid Based Complement Alternat Med* 5: 159–164.



53. Kiho T, Morimoto H, Kobayashi T, et al. (2000) Effect of a polysaccharide (TAP) from the fruiting bodies of *Tremella aurantia* on glucose metabolism in mouse liver. *Biosci Biotechnol Biochem* 64: 417–419.
54. Kiho T, Kochi M, Usui S, et al. (2001) Antidiabetic effect of an acidic polysaccharide (TAP) from *Tremella aurantia* and its degradation product (TAP-H). *Biol Pharm Bull* 24: 1400–1403.
55. Cho EJ, Hwang HJ, Kim SW, et al. (2007) Hypoglycemic effects of exopolysaccharides produced by mycelial cultures of two different mushrooms *Tremella fuciformis* and *Phellinus baumii* in ob/ob mice. *Appl Microbiol Biotechnol* 75: 1257–1265.
56. Fu M, Wang L, Wang XY, et al. (2018) Determination of the Five Main Terpenoids in Different Tissues of *Wolfiporia cocos*. *Molecules* 23: 1839.
57. Esteban CI (2009) Medicinal interest of *Poria cocos* (*Wolfiporia extensa*). *Rev Iberoam Micol* 26: 103–107.
58. Li Y, Zhang J, Li T, et al. (2016) A Comprehensive and Comparative Study of *Wolfiporia extensa* Cultivation Regions by Fourier Transform Infrared Spectroscopy and Ultra-Fast Liquid Chromatography. *PLoS One* 11: e0168998.
59. Shafrir E, Spielman S, Nachliel I, et al. (2001) Treatment of diabetes with vanadium salts: general overview and amelioration of nutritionally induced diabetes in the *Psammomys obesus gerbil*. *Diabetes Metab Res Rev* 17: 55–66.
60. Clark TA, Deniset JF, Heyliger CE, et al. (2014) Alternative therapies for diabetes and its cardiac complications: role of vanadium. *Heart Fail Rev* 19: 123–132.
61. Gruzewska K, Michno A, Pawelczyk T, et al. (2014) Essentiality and toxicity of vanadium supplements in health and pathology. *J Physiol Pharmacol* 65: 603–611.
62. Halberstam M, Cohen N, Shlimovich P, et al. (1996) Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. *Diabetes* 45: 659–666.
63. Huang HY, Korivi M, Chaing YY, et al. (2012) *Pleurotus tuber-regium* Polysaccharides Attenuate Hyperglycemia and Oxidative Stress in Experimental Diabetic Rats. *Evid Based Complement Alternat Med* 2012: 856381.
64. Huang HY, Korivi M, Yang HT, et al. (2014) Effect of *Pleurotus tuber-regium* polysaccharides supplementation on the progression of diabetes complications in obese-diabetic rats. *Chin J Physiol* 57: 198–208.
65. Kobayashi M, Kawashima H, Takemori K, et al. (2012) Ternatin, a cyclic peptide isolated from mushroom, and its derivative suppress hyperglycemia and hepatic fatty acid synthesis in spontaneously diabetic KK-A(y) mice. *Biochem Biophys Res Commun* 427: 299–304.
66. Laurino LF, Viroel FJM, Pickler TB, et al. (2017) Functional foods in gestational diabetes: Evaluation of the oral glucose tolerance test (OGTT) in pregnant rats treated with mushrooms. *Reprod Toxicol* 72: 36.
67. Jayasuriya WJ, Wanigatunge CA, Fernando GH, et al. (2015) Hypoglycaemic activity of culinary *Pleurotus ostreatus* and *P. cystidiosus* mushrooms in healthy volunteers and type 2 diabetic patients on diet control and the possible mechanisms of action. *Phytother Res* 29: 303–309.
68. Gao Y, Lan J, Dai X, et al. (2004) A Phase I/II Study of Ling Zhi Mushroom *Ganoderma lucidum* (W.Curt.:Fr.) Lloyd (Aphyllophoromycetidae) Extract in Patients with Type II Diabetes Mellitus. *Int J Med Mushrooms* 6: 327–334.

- 
69. Friedman M (2016) Mushroom Polysaccharides: Chemistry and Antiobesity, Antidiabetes, Anticancer, and Antibiotic Properties in Cells, Rodents, and Humans. *Foods* 5: 80.
  70. Lo HC, Wasser SP (2011) Medicinal mushrooms for glycemic control in diabetes mellitus: history, current status, future perspectives, and unsolved problems (review). *Int J Med Mushrooms* 13: 401–426.



**AIMS Press**

© 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>)